Top

Published in:

Open Access 01-04-2019 | Metastasis | Preclinical study

Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior

Authors: C. D. Savci-Heijink, H. Halfwerk, G. K. J. Hooijer, J. Koster, H. M. Horlings, S. L. Meijer, M. J. van de Vijver

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Abstract

Background

Epithelial-to-mesenchymal transition (EMT) has been implicated as an important step in the development of distant metastases. We therefore wished to study EMT status of primary breast carcinomas from patients who during follow-up developed distant metastases.

Methods

mRNA expression profiles of primary breast carcinoma samples (n = 151) from patients who developed metastatic disease were analyzed and EMT status was designated using a previously described EMT-core signature. EMT status of the primary tumor was correlated to clinicopathological characteristics, molecular subtypes, metastasis pattern, chemotherapy response and survival outcomes. In addition, using immunohistochemistry, the expression levels of several proteins implicated in EMT were studied (CDH1, CDH2, NAT1, SNAI2, TWIST1, VIM, and ZEB1) compared with the designated EMT status and survival.

Results

Utilizing the 130-gene-EMT-core signature, 66.2% of the primary tumors in the current study was assessed as EMT-activated. In contrast to our expectations, analyses revealed that 84.6% of Luminal A tumors, 65.1% of Luminal B tumors, and 55.6% of HER2-like had an activated EMT status, compared to only 25% of the basal-type tumors (p < 0.001). EMT status was not correlated to the pattern of metastatic disease, metastasis-specific survival, and overall survival. Similarly, there was not a significant association between EMT status of the primary tumor and chemotherapy response in the metastatic setting. Immunostaining for NAT1 and TWIST1 correlated with the EMT status (p 0.003 and p 0.047, respectively). Multivariate analyses showed that NAT1 and TWIST1 staining was significantly associated with EMT status regardless of the estrogen receptor status of the tumors (p values: 0.020 and 0.027, respectively).

Conclusions

The EMT status of breast cancers, as defined by the presence of a core EMT gene expression signature is associated with non-basal-type tumors, but not with the pattern of distant metastasis. Of several potential immunohistochemical EMT markers, only NAT1 and TWIST1 expression levels were associated with the gene expression-based EMT status.

Available only for authorised users

Abell AN, Jordan NV, Huang W, Prat A, Midland AA, Johnson NL, Granger DA, Mieczkowski PA, Perou CM, Gomez SM, Li L, Johnson GL (2011) MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. Cell Stem Cell 8:525–537. https://doi.org/10.1016/j.stem.2011.03.008 CrossRefPubMedPubMedCentral

Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P, De Belin J, Steers G, Pezzella F, Sachsenmeir KF, Stamps AC, Herath A, Sim E, O’Hare MJ, Harris AL, Terrett JA (2003) Arylamine -acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res 1:826–835PubMed

Brabletz T (2012) To differentiate or not–routes towards metastasis. Nat Rev Cancer 12:425–436. https://doi.org/10.1038/nrc3265 CrossRefPubMed

Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R, Kirchner T (2001) Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 98:10356–10361. https://doi.org/10.1073/pnas.171610498 CrossRefPubMedPubMedCentral

Butcher NJ, Minchin RF (2012) Arylamine N-acetyltransferase 1: a novel drug target in cancer development. Pharmacol Rev 64:147–165. https://doi.org/10.1124/pr.110.004275 CrossRefPubMed

Cheng GZ, Zhang W, Wang LH (2008) Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay. Cancer Res 68:957–960. https://doi.org/10.1158/0008-5472.CAN-07-5067 CrossRefPubMed

Christiansen JJ, Rajasekaran AK (2006) Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66:8319–8326. https://doi.org/10.1158/0008-5472.CAN-06-0410 CrossRefPubMed

Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106:13820–13825. https://doi.org/10.1073/pnas.0905718106 CrossRefPubMedPubMedCentral

Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L, Yang J (2011) Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 19:372–386. https://doi.org/10.1016/j.ccr.2011.01.036 CrossRefPubMedPubMedCentral

10.

Elias MC, Tozer KR, Silber JR, Mikheeva S, Deng M, Morrison RS, Manning TC, Silbergeld DL, Glackin CA, Reh TA, Rostomily RC (2005) TWIST is expressed in human gliomas and promotes invasion. Neoplasia 7:824–837CrossRefPubMedPubMedCentral

11.

Endo Y, Yamashita H, Takahashi S, Sato S, Yoshimoto N, Asano T, Hato Y, Dong Y, Fujii Y, Toyama T (2014) Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer. BMC Cancer 14:990. https://doi.org/10.1186/1471-2407-14-990 CrossRefPubMedPubMedCentral

12.

Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, Mittal V, Gao D (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527:472–476. https://doi.org/10.1038/nature15748 CrossRefPubMedPubMedCentral

13.

Frisch SM, Schaller M, Cieply B (2013) Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci 126:21–29. https://doi.org/10.1242/jcs.120907 CrossRefPubMedPubMedCentral

14.

Gort EH, Suijkerbuijk KP, Roothaan SM, Raman V, Vooijs M, van der Wall E, van Diest PJ (2008) Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. Cancer Epidemiol Biomarkers Prev 17:3325–3330. https://doi.org/10.1158/1055-9965.EPI-08-0472 CrossRefPubMed

15.

Groger CJ, Grubinger M, Waldhor T, Vierlinger K, Mikulits W (2012) Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS ONE 7:e51136. https://doi.org/10.1371/journal.pone.0051136 CrossRefPubMedPubMedCentral

16.

Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zurrer-Hardi U, Bell G, Tam WL, Mani SA, van Oudenaarden A, Weinberg RA (2012) Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148:1015–1028. https://doi.org/10.1016/j.cell.2012.02.008 CrossRefPubMedPubMedCentral

17.

Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM (2012) Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer ResTreat 132:523–535. https://doi.org/10.1007/s10549-011-1619-7 CrossRef

18.

Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8:R76. https://doi.org/10.1186/gb-2007-8-5-r76 CrossRefPubMedPubMedCentral

19.

Huang RY, Wong MK, Tan TZ, Kuay KT, Ng AH, Chung VY, Chu YS, Matsumura N, Lai HC, Lee YF, Sim WJ, Chai C, Pietschmann E, Mori S, Low JJ, Choolani M, Thiery JP (2013) An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis 4:e915. https://doi.org/10.1038/cddis.2013.442 CrossRefPubMedPubMedCentral

20.

Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, Kikkawa F (2007) Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31:277–283PubMed

21.

Kong D, Li Y, Wang Z, Sarkar FH (2011) Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? Cancers (Basel) 3:716–729. https://doi.org/10.3390/cancers30100716 CrossRef

22.

Laurieri N, Crawford MH, Kawamura A, Westwood IM, Robinson J, Fletcher AM, Davies SG, Sim E, Russell AJ (2010) Small molecule colorimetric probes for specific detection of human arylamine N-acetyltransferase 1, a potential breast cancer biomarker. J Am Chem Soc 132:3238–3239. https://doi.org/10.1021/ja909165u CrossRefPubMed

23.

Lee JM, Dedhar S, Kalluri R, Thompson EW (2006) The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172:973–981. https://doi.org/10.1083/jcb.200601018 CrossRefPubMedPubMedCentral

24.

Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL, Fan ST (2006) Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12:5369–5376. https://doi.org/10.1158/1078-0432.CCR-05-2722 CrossRefPubMed

25.

Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679. https://doi.org/10.1093/jnci/djn123 CrossRefPubMed

26.

Martin TA, Goyal A, Watkins G, Jiang WG (2005) Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann of Surg Oncol 12:488–496. https://doi.org/10.1245/ASO.2005.04.010 CrossRef

27.

McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL (2009) Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Investig 119:2663–2677. https://doi.org/10.1172/JCI37691 CrossRefPubMedPubMedCentral

28.

Mehrotra J, Vali M, McVeigh M, Kominsky SL, Fackler MJ, Lahti-Domenici J, Polyak K, Sacchi N, Garrett-Mayer E, Argani P, Sukumar S (2004) Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res 10:3104–3109CrossRefPubMed

29.

Mironchik Y, Winnard PT Jr, Vesuna F, Kato Y, Wildes F, Pathak AP, Kominsky S, Artemov D, Bhujwalla Z, Van Diest P, Burger H, Glackin C, Raman V (2005) Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res 65:10801–10809. https://doi.org/10.1158/0008-5472.CAN-05-0712 CrossRefPubMedPubMedCentral

30.

Nieto MA (2013) Epithelial plasticity: a common theme in embryonic and cancer cells. Science 342:1234850. https://doi.org/10.1126/science.1234850 CrossRefPubMed

31.

Ou DL, Chien HF, Chen CL, Lin TC, Lin LI (2008) Role of Twist in head and neck carcinoma with lymph node metastasis. Anticancer Res 28:1355–1359PubMed

32.

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167. https://doi.org/10.1200/JCO.2008.18.1370 CrossRefPubMedPubMedCentral

33.

Prall F (2007) Tumour budding in colorectal carcinoma. Histopathology 50:151–162. https://doi.org/10.1111/j.1365-2559.2006.02551.x CrossRefPubMed

34.

Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148:349–361. https://doi.org/10.1016/j.cell.2011.11.025 CrossRefPubMedPubMedCentral

35.

Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989–997. https://doi.org/10.1158/0008-5472.CAN-07-2017 CrossRefPubMed

36.

Satoh K, Hamada S, Kimura K, Kanno A, Hirota M, Umino J, Fujibuchi W, Masamune A, Tanaka N, Miura K, Egawa S, Motoi F, Unno M, Vonderhaar BK, Shimosegawa T (2008) Up-regulation of MSX2 enhances the malignant phenotype and is associated with twist 1 expression in human pancreatic cancer cells. Am J Pathol 172:926–939. https://doi.org/10.2353/ajpath.2008.070346 CrossRefPubMedPubMedCentral

37.

Savci-Heijink CD, Halfwerk H, Hooijer GK, Horlings HM, Wesseling J, van de Vijver MJ (2015) Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat 150:547–557. https://doi.org/10.1007/s10549-015-3352-0 CrossRefPubMedPubMedCentral

38.

Savci-Heijink CD, Halfwerk H, Koster J, Van de Vijver MJ (2017) Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer. BMC Cancer 17:755. https://doi.org/10.1186/s12885-017-3691-9 CrossRefPubMedPubMedCentral

39.

Savci-Heijink CD, Halfwerk H, Koster J, van de Vijver MJ (2016) A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Res Treat 156:249–259. https://doi.org/10.1007/s10549-016-3741-z CrossRefPubMedPubMedCentral

40.

Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741–4751. https://doi.org/10.1038/onc.2010.215 CrossRefPubMedPubMedCentral

41.

Strizzi L, Bianco C, Normanno N, Seno M, Wechselberger C, Wallace-Jones B, Khan NI, Hirota M, Sun Y, Sanicola M, Salomon DS (2004) Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol 201:266–276. https://doi.org/10.1002/jcp.20062 CrossRefPubMed

42.

Sugamori KS, Wong S, Gaedigk A, Yu V, Abramovici H, Rozmahel R, Grant DM (2003) Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. Mol Pharmacol 64:170–179. https://doi.org/10.1124/mol.64.1.170 CrossRefPubMed

43.

Tam WL, Weinberg RA (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19:1438–1449. https://doi.org/10.1038/nm.3336 CrossRefPubMedPubMedCentral

44.

Tan TZ, Miow QH, Miki Y, Noda T, Mori S, Huang RY, Thiery JP (2014) Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med 6:1279–1293. https://doi.org/10.15252/emmm.201404208 CrossRefPubMedPubMedCentral

45.

Tarin D, Thompson EW, Newgreen DF (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65:5996–6000. https://doi.org/10.1158/0008-5472.CAN-05-0699 discussion 6000–5991.CrossRefPubMed

46.

Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA (2010) Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 107:15449–15454. https://doi.org/10.1073/pnas.1004900107 CrossRefPubMedPubMedCentral

47.

Terauchi M, Kajiyama H, Yamashita M, Kato M, Tsukamoto H, Umezu T, Hosono S, Yamamoto E, Shibata K, Ino K, Nawa A, Nagasaka T, Kikkawa F (2007) Possible involvement of TWIST in enhanced peritoneal metastasis of epithelial ovarian carcinoma. Clin Exp Metastasis 24:329–339. https://doi.org/10.1007/s10585-007-9070-1 CrossRefPubMed

48.

Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890. https://doi.org/10.1016/j.cell.2009.11.007 CrossRefPubMed

49.

Tiang JM, Butcher NJ, Cullinane C, Humbert PO, Minchin RF (2011) RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS ONE 6:e17031. https://doi.org/10.1371/journal.pone.0017031 CrossRefPubMedPubMedCentral

50.

Tiang JM, Butcher NJ, Minchin RF (2015) Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines. Cancer Med 4:565–574. https://doi.org/10.1002/cam4.415 CrossRefPubMedPubMedCentral

51.

Tiang JM, Butcher NJ, Minchin RF (2010) Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 393:95–100. https://doi.org/10.1016/j.bbrc.2010.01.087 CrossRefPubMed

52.

Tseng JC, Chen HF, Wu KJ (2015) A twist tale of cancer metastasis and tumor angiogenesis. Histol Histopathol 30:1283–1294. https://doi.org/10.14670/HH-11-638 CrossRefPubMed

53.

Vermeulen E, Geesink I, Schmidt MK, Steegers C, Verhue D, Brom FW, Aaronson NK, van Leeuwen FE (2009) [Secondary use of human tissue: consent and better information required]. NedTijdschrGeneeskd 153:A948

54.

Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G (2006) Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9:261–272. https://doi.org/10.1016/j.ccr.2006.03.010 CrossRefPubMed

55.

Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J (2007) Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67:2649–2656. https://doi.org/10.1158/0008-5472.CAN-06-1823 CrossRefPubMed

56.

Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM, Ellis LM (2006) Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12:4147–4153. https://doi.org/10.1158/1078-0432.CCR-06-0038 CrossRefPubMed

57.

Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927–939. https://doi.org/10.1016/j.cell.2004.06.006 CrossRefPubMed

58.

Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, Huang CH, Kao SY, Tzeng CH, Tai SK, Chang SY, Lee OK, Wu KJ (2010) Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 12:982–992. https://doi.org/10.1038/ncb2099 CrossRefPubMed

59.

Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E, Weinberg RA (2015) Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525:256–260. https://doi.org/10.1038/nature14897 CrossRefPubMedPubMedCentral

60.

Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339:580–584. https://doi.org/10.1126/science.1228522 CrossRefPubMedPubMedCentral

61.

Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW (2007) Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology 50:648–658. https://doi.org/10.1111/j.1365-2559.2007.02665.x CrossRefPubMed

62.

Zhang Y, Toy KA, Kleer CG (2012) Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Modern Pathol 25:178–184. https://doi.org/10.1038/modpathol.2011.167 CrossRef

63.

Zhang Z, Xie D, Li X, Wong YC, Xin D, Guan XY, Chua CW, Leung SC, Na Y, Wang X (2007) Significance of TWIST expression and its association with E-cadherin in bladder cancer. Human Pathol 38:598–606. https://doi.org/10.1016/j.humpath.2006.10.004 CrossRef

64.

Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527:525–530. https://doi.org/10.1038/nature16064 CrossRefPubMedPubMedCentral

Title: Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior
Authors: C. D. Savci-Heijink
H. Halfwerk
G. K. J. Hooijer
J. Koster
H. M. Horlings
S. L. Meijer
M. J. van de Vijver
Publication date: 01-04-2019
Publisher: Springer US
Keywords: Metastasis
Breast Cancer
Breast Cancer
Cytostatic Therapy
Published in: Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-05089-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC

National consensus recommendations on patient-centered care for ductal carcinoma in situ

Clinical implications of germline mutations in breast cancer genes: RECQL

BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients

Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?

Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer